Страна: Канада
Език: английски
Източник: Health Canada
FLUVOXAMINE MALEATE
APOTEX INC
N06AB08
FLUVOXAMINE
100MG
TABLET
FLUVOXAMINE MALEATE 100MG
ORAL
100/250
Prescription
SELECTIVE-SEROTONIN REUPTAKE INHIBITORS
Active ingredient group (AIG) number: 0122450001; AHFS:
APPROVED
1997-05-12
Page 1 of 51 PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR APO-FLUVOXAMINE Fluvoxamine Maleate Tablets Tablets, 50 mg and 100 mg, Oral BP Antidepressant, Antiobsessional Agent SEP 21, 2022 _ _ CONTROL NUMBER:_ _266973_ _ _ _ _ _ APOTEX INC. 150 SIGNET DRIVE TORONTO, ONTARIO M9L 1T9 DATE OF INITIAL AUTHORIZATION: MAY 12, 1997 DATE OF REVISION: Page 2 of 51 RECENT MAJOR LABEL CHANGES 7 WARNINGS AND PRECAUTIONS 09/2022 7 WARNINGS AND PRECAUTIONS, 7.1.1 Pregnant Women 09/2022 7 WARNINGS AND PRECAUTIONS, Hematologic 09/2022 7 WARNINGS AND PRECAUTIONS, Serotonin Toxicity/Neuroleptic Malignant Syndrome 09/2022 7 WARNINGS AND PRECAUTIONS, Reproductive Health: Male and Female Potential 09/2022 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGES ........................................................................................................2 TABLE OF CONTENTS ..........................................................................................................................2 PART I: HEALTH PROFESSIONAL INFORMATION ..................................................................................4 1 INDICATIONS ..................................................................................................................................4 1.1 Pediatrics ....................................................................................................................................... 4 1.2 Geriatrics ....................................................................................................................................... 4 2 CONTRAINDICATIONS ..................................................................................................................4 4 DOSAGE AND ADMINISTRATION ..................................................................................................5 4.1 Dosing Considerations ...................................................................................... Прочетете целия документ